Asset Allocation
| Position | Category/Sector | Target Weight |
|---|---|---|
NVO Novo Nordisk A/S | Healthcare | 15% |
LLY Eli Lilly and Company | Healthcare | 15% |
AMGN Amgen Inc. | Healthcare | 13% |
AZN AstraZeneca PLC | Healthcare | 11% |
REGN Regeneron Pharmaceuticals, Inc. | Healthcare | 10% |
ALNY Alnylam Pharmaceuticals, Inc. | Healthcare | 10% |
TEVA Teva Pharmaceutical Industries Limited | Healthcare | 10% |
MCK McKesson Corporation | Healthcare | 8% |
VKTX Viking Therapeutics, Inc. | Healthcare | 7% |
HIMS Hims & Hers Health, Inc. | Consumer Defensive | 1% |
Find the right asset allocation for GLP Weigh Loss
Add portfolio to the optimizer to find optimal allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio OptimizerPerformance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in GLP Weigh Loss , comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.
Loading charts...
Returns By Period
| Position | 1D | 1M | YTD | 6M | 1Y | 3Y* | 5Y* | 10Y* |
|---|---|---|---|---|---|---|---|---|
Benchmark S&P 500 Index | 0.30% | 0.09% | 8.18% | 8.17% | 23.42% | 19.88% | 11.91% | 13.45% |
Portfolio GLP Weigh Loss | -1.65% | -0.72% | -5.05% | -1.48% | 18.39% | 24.73% | 27.18% | — |
| Portfolio components: | ||||||||
ALNY Alnylam Pharmaceuticals, Inc. | -3.59% | -0.98% | -26.53% | -32.06% | -2.88% | 15.25% | 13.17% | 16.55% |
AMGN Amgen Inc. | -1.10% | 5.02% | 7.16% | 9.19% | 22.66% | 20.11% | 11.06% | 11.65% |
AZN AstraZeneca PLC | -2.37% | -0.71% | 0.81% | 1.53% | 28.04% | 9.54% | 12.08% | 15.85% |
HIMS Hims & Hers Health, Inc. | 3.74% | -3.89% | -16.32% | -30.55% | -51.77% | 44.53% | 15.10% | — |
LLY Eli Lilly and Company | 1.57% | 21.37% | 7.29% | 15.58% | 50.32% | 38.07% | 39.75% | 33.71% |
MCK McKesson Corporation | -1.16% | 4.27% | -6.36% | -3.74% | 7.98% | 25.42% | 32.82% | 16.13% |
NVO Novo Nordisk A/S | -4.52% | -10.96% | -16.56% | -9.23% | -42.47% | -17.53% | 1.78% | 6.20% |
REGN Regeneron Pharmaceuticals, Inc. | -3.79% | -14.36% | -20.58% | -12.84% | 24.63% | -6.19% | 3.39% | 5.18% |
TEVA Teva Pharmaceutical Industries Limited | -2.72% | -6.91% | 6.57% | 17.40% | 87.17% | 65.55% | 25.39% | -4.15% |
VKTX Viking Therapeutics, Inc. | 2.78% | -6.67% | -16.88% | -23.01% | 5.07% | 6.41% | 39.22% | 36.31% |
Monthly Returns
Based on dividend-adjusted daily data since Sep 16, 2019, GLP Weigh Loss 's average daily return is +0.11%, while the average monthly return is +2.22%. At this rate, an investment would double in approximately 2.6 years.
Historically, 62% of months were positive and 38% were negative. The best month was Feb 2024 with a return of +20.2%, while the worst month was Oct 2020 at -8.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, GLP Weigh Loss closed higher 53% of trading days. The best single day was Feb 27, 2024 with a return of +14.1%, while the worst single day was Mar 12, 2020 at -9.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.41% | -0.24% | -6.22% | 1.50% | 2.14% | -2.52% | -5.05% | ||||||
| 2025 | 1.19% | 4.57% | -6.74% | 0.71% | -0.64% | 0.58% | -1.15% | 5.14% | 1.57% | 7.03% | 12.86% | -0.71% | 25.76% |
| 2024 | 8.35% | 20.24% | 4.85% | -0.64% | 6.26% | 8.53% | 0.09% | 7.58% | -6.87% | -3.80% | -4.93% | -5.31% | 35.94% |
| 2023 | 0.05% | -2.43% | 9.45% | 5.34% | -2.57% | 0.64% | 0.67% | 9.16% | -1.39% | -4.02% | 8.22% | 7.72% | 33.81% |
| 2022 | -6.24% | 2.73% | 9.11% | -4.44% | 2.33% | -0.12% | 4.10% | 1.65% | -3.40% | 13.39% | 5.48% | 11.91% | 40.43% |
| 2021 | 10.80% | -4.11% | 0.76% | 0.47% | 2.64% | 7.45% | 2.93% | 5.27% | -4.79% | 1.61% | -2.19% | 4.25% | 26.80% |
Benchmark Metrics
GLP Weigh Loss has an annualized alpha of 18.40%, beta of 0.70, and R2 of 0.38 versus S&P 500 Index. Calculated based on daily prices since September 16, 2019.
- This portfolio participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (93.63%) than losses (30.62%) - typical of diversified or defensive assets.
- Beta of 0.70 may look defensive, but with R2 of 0.38 this portfolio is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
- R2 of 0.38 means the benchmark explains less than half of this portfolio's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 18.40%
- Beta
- 0.70
- R²
- 0.38
- Upside Capture
- 93.63%
- Downside Capture
- 30.62%
Expense Ratio
GLP Weigh Loss has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.
Return for Risk
Risk / Return Rank
GLP Weigh Loss ranks 12 for risk / return — in the bottom 12% of Portfolios on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below presents risk-adjusted performance metrics for GLP Weigh Loss and compares them with S&P 500 Index.
| Portfolio | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | 0.88 | 1.94 | -1.05 |
| Sortino ratioReturn per unit of downside risk | 1.38 | 2.63 | -1.24 |
| Omega ratioGain probability vs. loss probability | 1.16 | 1.35 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | 1.41 | 2.59 | -1.17 |
| Martin ratioReturn relative to average drawdown | 3.48 | 11.84 | -8.37 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
How much return does each position deliver for the risk it carries? Higher values mean better reward for the risk taken.
| Position | Risk / Return Rank | Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Martin ratio |
|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals, Inc. | 38 | -0.08 | 0.15 | 1.02 | -0.07 | -0.12 |
AMGN Amgen Inc. | 66 | 0.83 | 1.40 | 1.17 | 1.37 | 3.21 |
AZN AstraZeneca PLC | 73 | 1.11 | 1.83 | 1.21 | 1.83 | 4.90 |
HIMS Hims & Hers Health, Inc. | 20 | -0.54 | -0.42 | 0.95 | -0.67 | -1.09 |
LLY Eli Lilly and Company | 77 | 1.33 | 1.90 | 1.26 | 2.14 | 5.32 |
MCK McKesson Corporation | 49 | 0.28 | 0.65 | 1.08 | 0.29 | 0.79 |
NVO Novo Nordisk A/S | 12 | -0.82 | -1.01 | 0.86 | -0.77 | -1.14 |
REGN Regeneron Pharmaceuticals, Inc. | 64 | 0.75 | 1.26 | 1.16 | 0.96 | 3.20 |
TEVA Teva Pharmaceutical Industries Limited | 90 | 2.25 | 3.42 | 1.43 | 4.02 | 10.94 |
VKTX Viking Therapeutics, Inc. | 46 | 0.07 | 0.63 | 1.10 | 0.11 | 0.23 |
Loading charts...
Dividends
Dividend yield
GLP Weigh Loss provided a 1.53% dividend yield over the last twelve months.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portfolio | 1.53% | 1.22% | 1.09% | 0.93% | 1.00% | 1.11% | 1.29% | 1.33% | 1.37% | 1.83% | 2.14% | 1.41% |
| Portfolio components: | ||||||||||||
ALNY Alnylam Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
AMGN Amgen Inc. | 2.83% | 2.91% | 3.45% | 2.96% | 2.95% | 3.13% | 2.78% | 2.41% | 2.71% | 2.65% | 2.74% | 1.95% |
AZN AstraZeneca PLC | 2.93% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
HIMS Hims & Hers Health, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.56% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
MCK McKesson Corporation | 0.43% | 0.37% | 0.47% | 0.50% | 0.54% | 0.72% | 0.95% | 1.16% | 1.32% | 0.80% | 0.80% | 0.53% |
NVO Novo Nordisk A/S | 4.39% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
REGN Regeneron Pharmaceuticals, Inc. | 0.60% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
VKTX Viking Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the GLP Weigh Loss . A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GLP Weigh Loss was 29.72%, occurring on Apr 8, 2025. Recovery took 160 trading sessions.
The current GLP Weigh Loss drawdown is 8.87%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -29.72%Apr 2025 | 7mo 7d | 7mo 21d | 1y 2moSep 2024 - Nov 2025 |
COVID crash2020 | -21.83%Mar 2020 | 1mo 9d | 25d | 2mo 4dFeb 2020 - Apr 2020 |
2020 correction2020 | -16.67%Oct 2020 | 3mo 11d | 2mo 17d | 5mo 28dJul 2020 - Jan 2021 |
Bear market2022 | -14.94%Jun 2022 | 2mo 6d | 1mo 19d | 3mo 25dApr 2022 - Aug 2022 |
Bear market2022 | -13.76%Sep 2022 | 1mo 11d | 1mo 2d | 2mo 13dAug 2022 - Oct 2022 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Diversification
Diversification Metrics
Number of Effective Assets
The portfolio contains 10 assets, with an effective number of assets of 8.67, reflecting the diversification based on asset allocation. Your capital is well-distributed across most of your holdings, with only mild concentration in a few names. True diversification also depends on the correlations between assets — check the diversification ratio below.
Diversification Ratio
1Y | 3Y | 5Y | All Time | |
|---|---|---|---|---|
Diversification Ratio | 1.89 | 1.88 | 1.89 | 1.77 |
The portfolio has a diversification ratio of 1.77, in line with the typical range across portfolios. There's room to improve by adding less correlated assets.
GLP Weigh Loss correlation to the S&P 500 Index
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.45 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.46 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.52 |
Correlation (All Time) Calculated using the full available price history since Sep 16, 2019 | 0.54 |
Benchmark Correlations
Correlation vs. S&P 500 Index. TEVA has the highest benchmark correlation at 0.40, while AZN has the lowest at 0.29.
Asset Correlations Table
| HIMS | MCK | TEVA | ALNY | VKTX | AZN | NVO | LLY | REGN | AMGN | |
|---|---|---|---|---|---|---|---|---|---|---|
| HIMS | 1.00 | 0.06 | 0.20 | 0.23 | 0.27 | 0.09 | 0.17 | 0.13 | 0.12 | 0.13 |
| MCK | 0.06 | 1.00 | 0.23 | 0.11 | 0.12 | 0.24 | 0.18 | 0.27 | 0.26 | 0.34 |
| TEVA | 0.20 | 0.23 | 1.00 | 0.27 | 0.30 | 0.25 | 0.21 | 0.21 | 0.23 | 0.26 |
| ALNY | 0.23 | 0.11 | 0.27 | 1.00 | 0.34 | 0.23 | 0.22 | 0.25 | 0.35 | 0.29 |
| VKTX | 0.27 | 0.12 | 0.30 | 0.34 | 1.00 | 0.23 | 0.27 | 0.25 | 0.26 | 0.25 |
| AZN | 0.09 | 0.24 | 0.25 | 0.23 | 0.23 | 1.00 | 0.42 | 0.38 | 0.35 | 0.40 |
| NVO | 0.17 | 0.18 | 0.21 | 0.22 | 0.27 | 0.42 | 1.00 | 0.44 | 0.34 | 0.30 |
| LLY | 0.13 | 0.27 | 0.21 | 0.25 | 0.25 | 0.38 | 0.44 | 1.00 | 0.36 | 0.40 |
| REGN | 0.12 | 0.26 | 0.23 | 0.35 | 0.26 | 0.35 | 0.34 | 0.36 | 1.00 | 0.49 |
| AMGN | 0.13 | 0.34 | 0.26 | 0.29 | 0.25 | 0.40 | 0.30 | 0.40 | 0.49 | 1.00 |
Find what GLP Weigh Loss is missing
See which holdings overlap, where GLP Weigh Loss is concentrated, and which low-correlation assets could fill the gaps.
Analyze Diversification